Search Result

Results for "

Liver X receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	LXR (20) Adiponectin Receptor (1) Autophagy (1) Dihydroorotate Dehydrogenase (2) Endogenous Metabolite (4) Estrogen Receptor/ERR (1) FXR (5) Interleukin Related (2) P2X Receptor (1) Sirtuin (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (10) Infection (2) Inflammation/Immunology (9) Metabolic Disease (8) Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Targets Recommended: LXR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-143259

BE1218

LXR Cancer

BE1218 is a liver X receptor (LXR) inverse agonist with IC₅₀ values of 9 nM and 7 nM against LXRα and LXRβ, respectively .

BE1218	LXR	Cancer
BE1218 is a liver X receptor (LXR) inverse agonist with IC₅₀ values of 9 nM and 7 nM against LXRα and LXRβ, respectively .

HY-14908

Vidofludimus 1 Publications Verification 4sc-101; SC12267	Dihydroorotate Dehydrogenase Interleukin Related FXR	Infection Inflammation/Immunology
Vidofludimus is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for *farnesoid X receptor* (FXR)*. Vidofludimus, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus also can be used for the research of fatty liver* by targeting FXR .

HY-N3216

Nagilactone B

LXR Cardiovascular Disease

Nagilactone B is a liver X receptor (LXR) agonist.

Nagilactone B	LXR	Cardiovascular Disease
Nagilactone B is a liver X receptor (LXR) agonist.

HY-146288

LXR agonist 2	LXR	Metabolic Disease
LXR agonist 2 (compound 18rr) is a potent LXR (liver X receptor) agonist. LXR agonist 2 can stabilize NCOA1 (co-activator), leading to LXR agonism .

HY-14908A

Vidofludimus hemicalcium 4sc-101 hemicalcium; SC12267 hemicalcium	Dihydroorotate Dehydrogenase Interleukin Related FXR	Infection Inflammation/Immunology
Vidofludimus (4sc-101; SC12267) hemicalcium is an orally active inhibitor for dihydroorotate dehydrogenase (DHODH) and also is a novel modulator for *farnesoid X receptor* (FXR)*. Vidofludimus hemicalcium, as an immunomodulatory agent, can be used for the research of autoimmune disorders such as inflammatory bowel disease (IBD). Vidofludimus hemicalcium also can be used for the research of fatty liver* by targeting FXR .

HY-N2371

27-Hydroxycholesterol 2 Publications Verification 27-OHC	Estrogen Receptor/ERR LXR Endogenous Metabolite	Cancer
27-Hydroxycholesterol (27-OHC) is a selective estrogen receptor modulator and an agonist of the **liver X receptor**.

HY-16972

SR9243

5 Publications Verification

LXR Cancer

SR9243 is a liver-X-receptor (LXR) inverse agonist that induces LXR-corepressor interaction.
HY-109073

Rovazolac

ALX-101
LXR Inflammation/Immunology

Rovazolac is a liver x receptor (LXR) modulator extracted from patent WO2013130892A1.
HY-101442

SR9238

LXR Metabolic Disease

SR9238 is a synthetic liver X receptor (LXR) inverse agonist with IC₅₀s of 214 nM and 43 nM for LXRα and LXRβ, respectively.

SR9243 5 Publications Verification	LXR	Cancer
SR9243 is a liver-X-receptor (LXR) inverse agonist that induces LXR-corepressor interaction.

Rovazolac ALX-101	LXR	Inflammation/Immunology
Rovazolac is a liver x receptor (LXR) modulator extracted from patent WO2013130892A1.

SR9238	LXR	Metabolic Disease
SR9238 is a synthetic liver X receptor (LXR) inverse agonist with IC₅₀s of 214 nM and 43 nM for LXRα and LXRβ, respectively.

HY-N2509

Iristectorigenin B Iristectrigenin B	LXR	Cardiovascular Disease
Iristectorigenin B (Iristectrigenin B) is a liver X receptor (LXR) modulator. Iristectrigenin B stimulates the transcriptional activity of both LXR-α and LXR-β .

HY-111498A

RGX-104 1 Publications Verification Abequolixron	LXR	Inflammation/Immunology Cancer
RGX-104 is an orally bioavailable and potent liver-X nuclear hormone receptor (LXR) agonist that modulates innate immunity via transcriptional activation of the ApoE gene.

HY-10627A

GW3965 hydrochloride Maximum Cited Publications 12 Publications Verification	LXR	Cardiovascular Disease Cancer
GW3965 hydrochloride is a potent and selective liver X receptor (LXR) agonist with EC₅₀s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively .

HY-10627

GW3965

LXR Cardiovascular Disease

GW3965 is a potent, selective liver X receptor (LXR) agonist with EC₅₀s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively .

GW3965	LXR	Cardiovascular Disease
GW3965 is a potent, selective liver X receptor (LXR) agonist with EC₅₀s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively .

HY-144549

LXR agonist 1	LXR	Cardiovascular Disease
LXR (Liver X receptor) agonist 1 is potent LXR agonist with AC₅₀s of 1.5 nM and 12 nM for LXR-α and LXR-β, respectively. LXR agonist 1 has the potential for the research of atherosclerosis .

HY-125772

Acetyl podocarpic acid anhydride Acetylpodocarpic dimer; APD	LXR	Cardiovascular Disease
Acetyl podocarpic acid anhydride is a potent, semisynthetic liver X receptor(LXR) agonist derived from extracts of the mayapple. Acetyl podocarpic acid anhydride has the potential to be useful for the prevention and research of atherosclerosis, especially in the context of low HDL levels .

HY-N2078

Yamogenin Neodiosgenin	LXR	Metabolic Disease
Yamogenin (Neodiosgenin) is a diastereomer of diosgenin. Yamogenin (Neodiosgenin) antagonizes the activation of the liver X receptor (LXR) in luciferase ligand assay. Yamogenin (Neodiosgenin) inhibits triacylglyceride (TG) accumulation through the suppression of gene expression of fatty acid synthesis in HepG2 hepatocytes .

HY-110267

DY268	FXR	Metabolic Disease
DY268 is a *farnesoid X receptor* (FXR) antagonist (IC₅₀*=7.5 nM). It inhibits FXR transactivation in a cell-based assay with an IC₅₀ value of 468 nM. DY268 can be used in the study of drug-induced liver* injury (DILI) .

HY-139576

Larsucosterol DUR-928	Endogenous Metabolite	Metabolic Disease
Larsucosterol (DUR-928), a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol as a potent endogenous regulator decreases lipogenesis. Larsucosterol inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-139576A

Larsucosterol sodium DUR-928 sodium	Endogenous Metabolite	Metabolic Disease
Larsucosterol (DUR-928) sodium, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol sodium as a potent endogenous regulator decreases lipogenesis. Larsucosterol sodium inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-100469

LXRβ agonist-2	LXR	Cardiovascular Disease
LXRβ agonist-2 is a highly potent and β-selective liver X receptor (LXRβ) agonist with EC₅₀ of 7 nM, displays 28.5-fold selectivity over LXRα (EC₅₀=200 nM) and used in the treatment of atherosclerosis .

HY-153114

HEC96719	FXR	Inflammation/Immunology
HEC96719 is a selective and orally active tricyclic farnesoid X receptor (FXR) agonist with EC₅₀ values of 1.37 and 1.55 nM by time-resolved fluorescence energy transfer (TR-FRET) and luciferase reporter assays, respectively. HEC96719 significantly improves non-alcoholic steatohepatitis (NASH) and liver fibrosis with favorable tissue distribution in liver and intestine. HEC96719 can be used for the research of non-alcoholic steatohepatitis .

HY-139576B

Larsucosterol (trimethylamine) DUR-928 (trimethylamine)	LXR Endogenous Metabolite	Metabolic Disease
Larsucosterol (DUR-928) trimethylamine, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol trimethylamine as a potent endogenous regulator decreases lipogenesis. Larsucosterol trimethylamine inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

HY-W040150

(24S,25)-Epoxycholesterol	LXR	Neurological Disease Inflammation/Immunology Cancer
24S,25-Epoxycholesterol is an agonist for Liver X Receptor (LXR). 24S,25-Epoxycholesterol exhibits properties in regulating the cholesterol efflux , inhibiting tumor growth against gastric cancer and glioblastoma and inducing apoptosis in BMMC cells .

HY-151959

FXR agonist 4	FXR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
FXR agonist 4 (compound 10a) is an agonist of farnesoid X receptor (FXR) with an EC₅₀ value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD) .

HY-152262

LXRβ agonist-4	LXR	Inflammation/Immunology
LXRβ agonist-4 is a potent, orally active **Liver X receptors (LXRs) agonist with an IC₅₀** value of 0.0078 μM for LXRβ. LXRβ agonist-4 inhibits RANKL-induced osteoclast differentiation and bone resorption. LXRβ agonist-4 can be used in research of osteoporosis .

HY-D1734

FITC-GW3965	LXR	Cardiovascular Disease
FITC-GW3965 is a fluorescence-labelled liver X receptor β (LXRβ) agonist GW3965 (HY-10627). FITC-GW3965 is a tracer, that can be designed by replacing the trifluoromethyl of GW3965 with an amide to link the FITC. FITC-GW3965 can be used to study the function of LXRβ .

HY-146275

LXRβ agonist-3	LXR	Cancer
LXRβ agonist-3 (compound 4-13) is a potent and selective LXRβ (liver X receptor β) agonist, with an EC₅₀ of 0.095 μM. LXRβ agonist-3 efficiently inhibits U87EGFRvIII cell, with an IC₅₀ of 3.75 μM. LXRβ agonist-3 shows antitumor activity, and can inhibit glioblastoma .

HY-N9182

Zeaxanthin dipalmitate Physalien	Adiponectin Receptor P2X Receptor Autophagy	Inflammation/Immunology
Zeaxanthin dipalmitate (Physalien) is a wolfberry-derived carotenoid, has anti-inflammatory and anti-oxidative stress effects. Zeaxanthin dipalmitate directly interact with p2X7 receptor (K_d=81.2 nM) and *adiponectin receptor* 1 (AdipoR1; K_d=533 nM) in a positive dose-dependent manner. Zeaxanthin dipalmitate restores mitochondrial autophagy** functions suppressed by ethanol intoxication. Zeaxanthin dipalmitate can be used in the research of alcoholic fatty liver disease (AFLD) and retinitis pigmentosa (RP) .

HY-117006

E1231 1-{4-[2-(5-Methylfuran-2-yl)quinoline-4-carbonyl]piperazin-1-yl}ethan-1-one	Sirtuin	Cardiovascular Disease
E1231 is an orally active activator of Sirtuin 1 (SIRT1) (EC₅₀=0.83 μM), to modulate cholesterol and lipid metabolism. E1231 interactes with SIRT1 (K_D=9.61 μM) and deacetylated liver X receptor-alpha (LXRα), and increases ATP-binding cassette transporter A1 (ABCA1) expression. E1231 also reduces atherosclerotic plaque development in ApoE ^-/- mice model. E1231 can be used for research in cholesterol and lipid disorder-related diseases .

Nagilactone B	Other Terpenoids Cardiovascular Disease Podocarpus nagi Classification of Application Fields Terpenoids Source classification Plants Podocarpaceae Disease Research Fields	LXR
Nagilactone B is a liver X receptor (LXR) agonist.

27-Hydroxycholesterol 2 Publications Verification 27-OHC	Structural Classification Natural Products Classification of Application Fields Source classification Disease markers Nervous System Disorder Endogenous metabolite Disease Research Fields Cardiovascular System Disorder Cancer	Estrogen Receptor/ERR LXR Endogenous Metabolite
27-Hydroxycholesterol (27-OHC) is a selective estrogen receptor modulator and an agonist of the **liver X receptor**.

Iristectorigenin B Iristectrigenin B	Cardiovascular Disease Natural Products Iridaceae Classification of Application Fields Source classification Phenols Polyphenols Plants Belamcanda chinensis (Linn.) Redouté Disease Research Fields	LXR
Iristectorigenin B (Iristectrigenin B) is a liver X receptor (LXR) modulator. Iristectrigenin B stimulates the transcriptional activity of both LXR-α and LXR-β .

Yamogenin Neodiosgenin	other families Classification of Application Fields Source classification Metabolic Disease Plants Disease Research Fields Steroids	LXR
Yamogenin (Neodiosgenin) is a diastereomer of diosgenin. Yamogenin (Neodiosgenin) antagonizes the activation of the liver X receptor (LXR) in luciferase ligand assay. Yamogenin (Neodiosgenin) inhibits triacylglyceride (TG) accumulation through the suppression of gene expression of fatty acid synthesis in HepG2 hepatocytes .

Larsucosterol DUR-928	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
Larsucosterol (DUR-928), a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol as a potent endogenous regulator decreases lipogenesis. Larsucosterol inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

Larsucosterol sodium DUR-928 sodium	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
Larsucosterol (DUR-928) sodium, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol sodium as a potent endogenous regulator decreases lipogenesis. Larsucosterol sodium inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

Larsucosterol (trimethylamine) DUR-928 (trimethylamine)	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	LXR Endogenous Metabolite
Larsucosterol (DUR-928) trimethylamine, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol trimethylamine as a potent endogenous regulator decreases lipogenesis. Larsucosterol trimethylamine inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1 .

Zeaxanthin dipalmitate Physalien	Classification of Application Fields Terpenoids Source classification Diterpenoids Plants Solanaceae Lycium chinense Miller Disease Research Fields Inflammation/Immunology	Adiponectin Receptor P2X Receptor Autophagy
Zeaxanthin dipalmitate (Physalien) is a wolfberry-derived carotenoid, has anti-inflammatory and anti-oxidative stress effects. Zeaxanthin dipalmitate directly interact with p2X7 receptor (K_d=81.2 nM) and *adiponectin receptor* 1 (AdipoR1; K_d=533 nM) in a positive dose-dependent manner. Zeaxanthin dipalmitate restores mitochondrial autophagy** functions suppressed by ethanol intoxication. Zeaxanthin dipalmitate can be used in the research of alcoholic fatty liver disease (AFLD) and retinitis pigmentosa (RP) .

Species:	Human (2)
Tag:	His (1) Tag Free (1)
Source:	E. coli (2)

	LXR-α Protein, Human NR1H3; Oxysterols receptor LXR-alpha; Liver X receptor alpha; Nuclear receptor subfamily 1 group H member 3	Human	E. coli
	LXR-α protein is a nuclear receptor that activates transcription by interacting with RXR. It regulates cholesterol uptake through MYLIP-dependent ubiquitination and is critical for cholesterol homeostasis. LXR-α Protein, Human is the recombinant human-derived LXR-α protein, expressed by E. coli , with tag free. The total length of LXR-α Protein, Human is 266 a.a., .

	LXR-α Protein, Human (His) NR1H3; Oxysterols receptor LXR-alpha; Liver X receptor alpha; Nuclear receptor subfamily 1 group H member 3	Human	E. coli
	LXR-α protein is a nuclear receptor that activates transcription by interacting with RXR. It regulates cholesterol uptake through MYLIP-dependent ubiquitination and is critical for cholesterol homeostasis. LXR-α Protein, Human (His) is the recombinant human-derived LXR-α protein, expressed by E. coli , with N-6*His labeled tag. The total length of LXR-α Protein, Human (His) is 266 a.a., .


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Liver X receptor

Inhibitors & Agonists

NaturalProducts

Recombinant Proteins

Natural
Products